<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38460" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Niacin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Djadjo</surname>
            <given-names>Soraya</given-names>
          </name>
          <aff>Ross University School of medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Tushar</given-names>
          </name>
          <aff>University of Chicago</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Soraya Djadjo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tushar Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38460.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The uses of niacin are yet to be fully comprehended and embraced. This activity assists in improving knowledge of the benefits niacin has to offer, not only for treatment but also in decreasing the incidence of certain diseases. This activity reviews the pharmacokinetic, administration, indications, contraindications, adverse effects, monitoring, toxicity, and, most importantly, how to enhance interprofessional team outcomes by effectively monitoring the use of this medication.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications for initiating therapy with niacin.</p></list-item><list-item><p>Explain the pharmacokinetics and administration of niacin.</p></list-item><list-item><p>Outline niacin's adverse effects, contraindications, and toxicity.</p></list-item><list-item><p>Review why interprofessional teamwork among members of the healthcare field is necessary for educating patients taking niacin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38460&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38460">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38460.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Niacin (a combination of nicotinic acid and nicotinamide), a B vitamin (vitamin B3), is a pharmacotherapeutic agent that has been used since 1955, making it the oldest pleiotropic hypolipidemic agent.<xref ref-type="bibr" rid="article-38460.r1">[1]</xref> The vitamin plays a role in both neuroprotection and neuronal death, giving&#x000a0;it the utmost importance in the proper functioning of the central nervous system (CNS), neuronal development, and function.<xref ref-type="bibr" rid="article-38460.r2">[2]</xref></p>
        <p>Niacin has seen extensive use, alone or in combination, with statin medications (hydroxymethyl glutaryl coenzyme A reductase inhibitors) in the reduction of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL), and lipoprotein levels. Moreover, niacin is the most potent agent used to increase plasma high-density lipoprotein (HDL) cholesterol.<xref ref-type="bibr" rid="article-38460.r3">[3]</xref>&#x000a0;In patients with diabetes mellitus or mixed dyslipidemia, niacin has demonstrated in clinical trials that it can counterbalance cardiovascular risk in this patient population, decreasing cardiovascular morbidity and mortality, especially when combined with statin drugs.<xref ref-type="bibr" rid="article-38460.r4">[4]</xref></p>
        <p>Niacin being such a pleiotropic agent still possesses properties that remain uncovered. Some other studied uses of niacin other than those stated above include the following.<xref ref-type="bibr" rid="article-38460.r5">[5]</xref>&#x000a0;It decreases&#x000a0; the incidence of cardiovascular events, premature aging, age-associated neurological disorders such as<xref ref-type="bibr" rid="article-38460.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Arthritis<xref ref-type="bibr" rid="article-38460.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Alzheimer disease</p>
          </list-item>
          <list-item>
            <p>Huntington disease</p>
          </list-item>
          <list-item>
            <p>Schizophrenia<xref ref-type="bibr" rid="article-38460.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Amyotrophic lateral sclerosis</p>
          </list-item>
          <list-item>
            <p>Muscular atrophy</p>
          </list-item>
          <list-item>
            <p>hyperphosphatemia in chronic kidney disease<xref ref-type="bibr" rid="article-38460.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Parkinson disease</p>
          </list-item>
          <list-item>
            <p>Squamous cell carcinoma<xref ref-type="bibr" rid="article-38460.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>It also has therapeutic use in treating diabetic encephalopathy,&#x000a0;malignant glioma, neurodegenerative diseases<xref ref-type="bibr" rid="article-38460.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Circadian rhythm and metabolism regulation through sirtuins</p>
          </list-item>
          <list-item>
            <p>Intracellular calcium regulation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38460.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>After undergoing biochemical reactions in the mitochondria with nicotinamide and tryptophan, niacin forms nicotinamide adenine dinucleotide (NAD) and NAD phosphate (NADP). NAD and NADP are the active forms of niacin which, when reduced to NAD(H) and NADP(H) respectively, participate in catabolic redox reactions and are cofactors in anabolic redox reactions.</p>
        <p>Although niacin has been in use for many years, its beneficial pleiotropic effects make it challenging to fully grasp its mechanism of action. However, a targeted mechanism of action based on certain effects niacin has in the human body are:</p>
        <list list-type="order">
          <list-item>
            <p>Lipid metabolism: Lipid-lowering ability of niacin is very diverse and still under investigation. One proposed mechanism is the action of niacin's antilipolytic effect, thought to be mediated via nicotinic acid receptors. An alternate mechanism recently uncovered is the ability of niacin to speed up the intracellular degradation of Apolipoprotein B (ApoB) containing lipoproteins, such as VLDL and LDL, by inhibiting triglyceride synthesis. Also, niacin inhibits diacylglycerol acyltransferase 2 (DGAT2), thereby decreasing hepatic triglyceride synthesis. A suggested mechanism for increasing HDL-cholesterol levels is that niacin decreases the degradation of ApoA-I-containing lipoproteins and increases peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;) expression and enhances PPAR&#x003b3; transcriptional activity in macrophages.<xref ref-type="bibr" rid="article-38460.r11">[11]</xref> Levels of free fatty acids become lowered via niacin's downregulating action of cyclic adenosine monophosphate. By doing so, it decreases the most important intracellular mediator of pro-lipolytic stimuli.<xref ref-type="bibr" rid="article-38460.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Increased fasting glycemia: This is thought to be through the roles of niacin-responsive G protein-coupled receptor (GPR109a) and plasma-free fatty acids (FFAs). Though details of the mechanism are yet to be fully uncovered, research has observed a direct relationship has between insulin resistance in muscles and high FFA (in the form of lipid overload) concentrations in non-adipose tissues. Also, intestinal cells in vivo are shown to increase their local glucose uptake when GPR109a gets stimulated by niacin, which may contribute to loss of glycemic control.<xref ref-type="bibr" rid="article-38460.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Aging-related process and pathologies: Though yet fully uncovered, the mechanism of action through current research may be the inverse relation between nicotinamide adenine dinucleotide (NAD) concentrations and dietary niacin intake. Researchers have demonstrated that reduced intracellular NAD concentrations lead to the loss of a cell's power to undergo division and growth, leading to cell aging and death. NAD-dependent enzymes such as sirtuin proteins and poly(ADP-ribose) polymerase (PARP) provide continuous protection of the genome and are also necessary for the repair of damaged DNA. Researchers observed increased cancer incidence and reactive oxygen species with decreased PARP. Also, lifespan-extending effects of caloric restriction, mediated by sirtuins, have been associated with premature aging and disorders like Huntington and other age-associated neurological disorders in cells with defective sirtuins.<xref ref-type="bibr" rid="article-38460.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Malignant glioma:&#x000a0;Niacin may inhibit glioma cell invasion in vivo and in vitro. Epithelial-mesenchymal transition (EMT) is involved in the process of cell migration, adhesion, and polarity; it also has involvement in the downregulation of E-cadherin, an epithelial marker, and upregulation of Snail1, a mesenchymal marker, both processes which are important to the normal developmental of mesoderm and neural crest migration. Research has found tumor cells to have EMT-like processes, which give them the ability to recur and cause immunosuppression and cell invasion. The degradation of Snail1, an EMT-promoting transcription factor that leads to invasion of U251 glioblastoma multiforme cells, was found to be facilitated in cells with niacin treatment, thus leading to a decrease in tumor invasion.<xref ref-type="bibr" rid="article-38460.r15">[15]</xref><xref ref-type="bibr" rid="article-38460.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38460.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Niacin is available in two chemical forms. As nicotinic acid only, used for hyperlipoproteinemia or peripheral vascular disease. Another form is both nicotinic acid and nicotinamide (niacinamide), used for nutritional supplementation or pellagra.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral extended-release tablets come in 250 mg, 500 mg, 750 mg, 1000 mg, and 3000 mg strengths. Dosing of 1 to 3 grams/day was found to reduce serum LDL cholesterol and increase serum HDL cholesterol.<xref ref-type="bibr" rid="article-38460.r17">[17]</xref>&#x000a0;Research showed that a formulation of modified release niacin and crystalline immediate-release niacin offered similar results.<xref ref-type="bibr" rid="article-38460.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Immediate-release tablets are available in formulation ranging from 50 mg to 500 mg. Initial dosing should be as low as possible to decrease adverse effect reactions and slowly titrated, preferably no more than 500 mg over four weeks to the patient&#x02019;s response and tolerance.</p>
          </list-item>
          <list-item>
            <p>Reverses in insulin resistance induced by lipid overload and rapid reduction of plasma FFA were observed with acute administration of niacin.<xref ref-type="bibr" rid="article-38460.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>At the time of niacin administration, patients should avoid alcohol as it may increase the risk of pruritus and flushing. In addition, niacin therapy is not recommended in patients who chronically misuse alcohol due to an increased risk of hepatotoxicity.</p>
          </list-item>
        </list>
        <p>
<bold>Recommended Dosage for&#x000a0;</bold>
<bold>Pellagra</bold>
</p>
        <p>
<bold>Adults</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral dosage (nicotinic acid or nicotinamide/niacinamide): Up to 500 mg/day orally, depending on the severity of niacin deficiency.</p>
          </list-item>
          <list-item>
            <p>Intravenous or Intramuscular Dosage: 50 to 100 mg intramuscular five times daily, or 25 to 100 mg given by slow intravenous infusion twice daily, depending on the severity of niacin deficiency. Maximum: 500 mg/daily.</p>
          </list-item>
        </list>
        <p>
<bold>Children</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dosing is up to 300 mg/day given by slow intravenous infusion, depending on the severity of niacin deficiency.</p>
          </list-item>
        </list>
        <p>
<bold>Recommended Dosage for Hypercholesterolemia, Mixed Dyslipidemia or H</bold>
<bold>ypertriglyceridemia, Type IV or V</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Normal dosing is 1500 to 3000 mg/day orally, divided two or three times daily.</p>
          </list-item>
          <list-item>
            <p>Starting dose: 250 mg orally at bedtime, with a gradual increase of 250 mg/day every 4 to 7 days up to 2000 mg/day.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>After two months, the dosage may be increased to 250 to 500 mg/day every 2 to 4 weeks, with a maximum of 6000 mg/day.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Note: 325 mg aspirin 30 minutes before a dose may reduce flushing; The medication should be given without food.</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy Considerations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Niacin is FDA Pregnancy Category C. When used at high doses to treat conditions such as dyslipidemia, niacin may cause harm to an unborn fetus.</p>
          </list-item>
        </list>
        <p>
<bold>Breastfeeding Considerations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Harm may result in a nursing baby as niacin can pass into breast milk; therefore, nursing mothers should avoid the drug.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38460.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Reactions</bold>
</p>
        <p>Flushing: Niacin often causes generalized pruritus, and a burning sensation is usually limited to the face and chest and lasts 20 to 30 minutes. This adverse reaction, however, decreases in frequency&#x000a0;and severity with time.<xref ref-type="bibr" rid="article-38460.r4">[4]</xref> Pretreatment of 30 minutes with aspirin (up to 325 mg) can&#x000a0;help counter this side effect. Laropiprant, a potent, selective antagonist of prostaglandin D2( PGD2)-receptor subtype-1, not only helps reduce&#x000a0;this side effect of niacin but allows for optimal pharmacological dosing if needed.<xref ref-type="bibr" rid="article-38460.r18">[18]</xref></p>
        <p>One reaction to consider is niacin&#x02019;s effects (whether used alone or combined with statin&#x000a0;medications) on glycemic control in patients with dyslipidemia, regardless of their diabetes mellitus status. In non-diabetic patients with dyslipidemia, on average, five years of niacin therapy, whether used alone or in laropiprant combination therapy, was associated with a 34% increased risk of developing diabetes.<xref ref-type="bibr" rid="article-38460.r19">[19]</xref>&#x000a0;Also, niacin administration has been demonstrated&#x000a0;to increase fasting glycemic levels in patients with diabetes. Avoiding niacin therapy has been recommended in patients with metabolic syndrome or diabetes.<xref ref-type="bibr" rid="article-38460.r13">[13]</xref><xref ref-type="bibr" rid="article-38460.r5">[5]</xref></p>
        <p>Other adverse effects include hyperuricemia, gastrointestinal disorders, rash, increased homocysteine levels, hypotension, dyspepsia, elevations in AST and ALT, nausea, vomiting, and paresthesias.<xref ref-type="bibr" rid="article-38460.r5">[5]</xref><xref ref-type="bibr" rid="article-38460.r1">[1]</xref></p>
        <p>
<bold>Serious Adverse Reactions</bold>
</p>
        <p>Peptic ulcer disease, arrhythmias, anaphylaxis, hepatotoxicity, hepatic necrosis, fulminant, macular edema<xref ref-type="bibr" rid="article-38460.r1">[1]</xref></p>
      </sec>
      <sec id="article-38460.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to niacin include the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with active peptic ulcer disease</p>
          </list-item>
          <list-item>
            <p>Patients who have active liver disease or present with unexplained and persistent elevations in hepatic transaminases</p>
          </list-item>
          <list-item>
            <p>Patients with hypersensitivity to niacin or any component of this medication</p>
          </list-item>
          <list-item>
            <p>Patients with arterial bleeding</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38460.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>Laboratory monitoring is recommended in patients on niacin therapy due to its diverse side effects.</p>
          </list-item>
          <list-item>
            <p>In pre-diabetes or diabetic patients, frequent monitoring of blood glucose is necessary as niacin can increase fasting blood glucose. Patients on diabetic medications, such as acarbose, albiglutide, alogliptin, glipizide, or insulin, should also have blood glucose monitored frequently.<xref ref-type="bibr" rid="article-38460.r19">[19]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Niacin can cause an increase in uric acid, thus exerting an antagonist effect on medications for gouts, such as pegloticase and allopurinol.</p>
          </list-item>
          <list-item>
            <p>Niacin exerts an additive reaction with blood pressure medications (amlodipine clozapine, bisoprolol, diltiazem), opioids (morphine, oxycodone, tramadol, methadone), antipsychotics (quetiapine, risperidone)&#x000a0;phosphodiesterase&#x000a0;type&#x000a0;5&#x000a0;inhibitor (tadalafil), thus leading to hypotension. Frequent blood pressure checking is recommended. Also, niacin, in combination with some beta-blockers, may decrease its antihyperlipidemic efficacy.</p>
          </list-item>
          <list-item>
            <p>Niacin can increase the risk of bleeding by exerting an additive effect. Niacin has shown to not only cause a reduction in platelet counts (mean of -11% with 2000 mg) but to increase prothrombin time (mean of approximately +4%), leading to bleeding, especially when combined with anticoagulants such as apixaban, caplacizumab, or warfarin. Thus, a blood coagulation panel should be a routine test.</p>
          </list-item>
          <list-item>
            <p>Niacin also exerts an additive effect when combined with ceritinib, diazoxide leading to hyperglycemia.</p>
          </list-item>
          <list-item>
            <p>Phosphorus levels also require monitoring in patients at risk for hypophosphatemia as niacin can cause a decrease in phosphorus levels (mean of -13% with 2000 mg).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38460.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In pharmacological doses (e.g., 1000 to 3000 mg/day), flushing reaction associated with its crystalline nicotinic acid component (not nicotinamide) is the most common and studied the toxicity of niacin, which is both person-to-person and dose-dependent.<xref ref-type="bibr" rid="article-38460.r4">[4]</xref>&#x000a0;Other symptoms of toxicity may include dizziness, upset stomach, redness, itching, nausea, and vomiting.</p>
      </sec>
      <sec id="article-38460.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Niacin is a pharmacotherapeutic pleiotropic agent with properties still yet to be fully understood. It is encouraged that interprofessional healthcare team members&#x000a0;(clinicians, pharmacists,&#x000a0;nurse practitioners, physician assistants, primary care providers, nurses) stay updated on niacin's properties and side effects uncovered by ongoing research. Niacin can cause flushing, a significant adverse impact that significantly affects its compliance in patients. Knowing how to titrate from a minimal dose will help minimize such unwanted effects and benefit patient health outcomes. Close monitoring and periodic blood work on initiating or increasing the dosage of niacin&#x000a0;is necessary as it is known to increase the risk of bleeding, hypotension, hyperuricemia, and cause alterations in glycemic control. Its adverse effect on glycemic control in patients with dyslipidemia, both with or without diabetes, is one of its most concerning effects as it may cause diabetes in predisposed patients or make the management of diabetes a challenge. Using an interprofessional approach with each discipline contributing from their area of expertise will result in better patient outcomes and fewer adverse effects from niacin. [Level 5]</p>
      </sec>
      <sec id="article-38460.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38460&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38460">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38460/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38460">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38460.s11">
        <title>References</title>
        <ref id="article-38460.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liberopoulos</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>What restricts the clinical use of nicotinic acid?</article-title>
            <source>Curr Vasc Pharmacol</source>
            <year>2011</year>
            <month>Jul</month>
            <day>01</day>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>521</fpage>
            <page-range>521-30</page-range>
            <pub-id pub-id-type="pmid">21314634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fricker</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>The Influence of Nicotinamide on Health and Disease in the Central Nervous System.</article-title>
            <source>Int J Tryptophan Res</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1178646918776658</fpage>
            <pub-id pub-id-type="pmid">29844677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Effects of niacin on glucose control in patients with dyslipidemia.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>470</fpage>
            <page-range>470-8</page-range>
            <pub-id pub-id-type="pmid">18380993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wierzbicki</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Niacin: the only vitamin that reduces cardiovascular events.</article-title>
            <source>Int J Clin Pract</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-85</page-range>
            <pub-id pub-id-type="pmid">21401825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Florentin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liberopoulos</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Kei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mikhailidis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.</article-title>
            <source>Curr Vasc Pharmacol</source>
            <year>2011</year>
            <month>Jul</month>
            <day>01</day>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-400</page-range>
            <pub-id pub-id-type="pmid">21314635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HOFFER</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of arthritis by nicotinic acid and nicotinamide.</article-title>
            <source>Can Med Assoc J</source>
            <year>1959</year>
            <month>Aug</month>
            <day>15</day>
            <volume>81</volume>
            <issue>4</issue>
            <fpage>235</fpage>
            <page-range>235-8</page-range>
            <pub-id pub-id-type="pmid">14402370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Niacin-respondent subset of schizophrenia &#x02013; a therapeutic review.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2015</year>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>988</fpage>
            <page-range>988-97</page-range>
            <pub-id pub-id-type="pmid">25855923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taketani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamanaka-Okumura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tatsumi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Segawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Niacin and Chronic Kidney Disease.</article-title>
            <source>J Nutr Sci Vitaminol (Tokyo)</source>
            <year>2015</year>
            <volume>61 Suppl</volume>
            <fpage>S173</fpage>
            <page-range>S173-5</page-range>
            <pub-id pub-id-type="pmid">26598845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>WQ</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Niacin intake and risk of skin cancer in US women and men.</article-title>
            <source>Int J Cancer</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>140</volume>
            <issue>9</issue>
            <fpage>2023</fpage>
            <page-range>2023-2031</page-range>
            <pub-id pub-id-type="pmid">28152570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motawi</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Darwish</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hamed</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>El-Rigal</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Aboul Naser</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Coenzyme Q10 and niacin mitigate streptozotocin- induced diabetic encephalopathy in a rat model.</article-title>
            <source>Metab Brain Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>1519</fpage>
            <page-range>1519-1527</page-range>
            <pub-id pub-id-type="pmid">28560538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gille</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bodor</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Offermanns</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nicotinic acid: pharmacological effects and mechanisms of action.</article-title>
            <source>Annu Rev Pharmacol Toxicol</source>
            <year>2008</year>
            <volume>48</volume>
            <fpage>79</fpage>
            <page-range>79-106</page-range>
            <pub-id pub-id-type="pmid">17705685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montecucco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Quercioli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dallegri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Viviani</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Mach</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>New evidence for nicotinic acid treatment to reduce atherosclerosis.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>1457</fpage>
            <page-range>1457-67</page-range>
            <pub-id pub-id-type="pmid">20936932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer-Ficca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kirkland</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Niacin.</article-title>
            <source>Adv Nutr</source>
            <year>2016</year>
            <month>May</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>556</fpage>
            <page-range>556-8</page-range>
            <pub-id pub-id-type="pmid">27184282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guarente</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>NAD+ and sirtuins in aging and disease.</article-title>
            <source>Trends Cell Biol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>464</fpage>
            <page-range>464-71</page-range>
            <pub-id pub-id-type="pmid">24786309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Perfetto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ping</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Christian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Mar</month>
            <day>03</day>
            <volume>7</volume>
            <fpage>43173</fpage>
            <pub-id pub-id-type="pmid">28256591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nicotinic acid impairs assembly of leading edge in glioma cells.</article-title>
            <source>Oncol Rep</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>829</fpage>
            <page-range>829-836</page-range>
            <pub-id pub-id-type="pmid">28656206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johnson-Levonas</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>McCrary Sisk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mitchel</surname>
                <given-names>YB</given-names>
              </name>
            </person-group>
            <article-title>Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2014</year>
            <volume>10</volume>
            <fpage>279</fpage>
            <page-range>279-90</page-range>
            <pub-id pub-id-type="pmid">24855368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parhofer</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2009</year>
            <volume>5</volume>
            <fpage>901</fpage>
            <page-range>901-8</page-range>
            <pub-id pub-id-type="pmid">20016845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38460.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Preiss</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.</article-title>
            <source>Heart</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-203</page-range>
            <pub-id pub-id-type="pmid">26370223</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
